Jacobus Pfisterer Selected Research

Cytoreduction Surgical Procedures

1/2023	Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
9/2011	Surgery for recurrent ovarian cancer.
12/2006	Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jacobus Pfisterer Research Topics

Disease

48	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 09/2003
34	Neoplasms (Cancer) 12/2023 - 06/2002
14	Carcinoma (Carcinomatosis) 12/2023 - 01/2004
10	Ovarian Epithelial Carcinoma 01/2017 - 03/2006
6	Residual Neoplasm 01/2023 - 10/2004
3	Disease Progression 01/2020 - 08/2015
2	Alopecia (Baldness) 05/2015 - 04/2006
2	Ascites 07/2007 - 12/2006
1	Genomic Instability 02/2022
1	Vulvar Neoplasms (Vulvar Cancer) 12/2020
1	Thrombocytosis (Thrombocythemia) 01/2020
1	Necrosis 01/2020
1	Tertiary Lymphoid Structures 01/2018
1	Immune System Diseases (Immune Disorders) 01/2018
1	Endometrial Neoplasms (Endometrial Cancer) 03/2016
1	Renal Insufficiency (Renal Failure) 01/2016
1	Sepsis (Septicemia) 01/2016
1	Peritonitis 01/2016
1	Neutropenia 01/2016
1	Thrombocytopenia (Thrombopenia) 01/2016
1	Fistula 08/2015
1	Heart Failure 08/2015
1	Sarcoidosis (Schaumann Disease) 08/2015
1	Body Weight (Weight, Body) 12/2011
1	Hypertension (High Blood Pressure) 12/2011
1	Venous Thromboembolism 06/2008
1	Neoplasm Metastasis (Metastasis) 01/2008
1	Endometrioid Carcinoma 01/2008
1	Adenocarcinoma 01/2008
1	Fallopian Tube Neoplasms 04/2007
1	Diarrhea 04/2007
1	Papillary Carcinoma 01/2007
1	Transitional Cell Carcinoma 04/2005
1	Squamous Cell Carcinoma of Head and Neck 06/2004
1	Onycholysis 06/2002

Drug/Important Bio-Agent (IBA)

20	PlatinumIBA 01/2020 - 04/2005
19	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 09/2003
18	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 09/2003
10	Bevacizumab (Avastin)FDA Link 12/2023 - 12/2011
10	taxaneIBA 01/2019 - 04/2006
5	AntigensIBA 01/2019 - 06/2004
4	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2007
4	Gemcitabine FDA Link 01/2020 - 04/2006
4	abagovomabIBA 04/2013 - 01/2010
4	Cisplatin (Platino)FDA LinkGeneric 10/2006 - 09/2003
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2007
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2023 - 01/2022
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2022 - 01/2018
2	nintedanibIBA 02/2022 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2008
2	Hematoxylin (Haematoxylon)IBA 11/2015 - 03/2009
2	Eosine Yellowish-(YS) (Eosin)IBA 11/2015 - 03/2009
2	VaccinesIBA 01/2010 - 06/2004
2	Topotecan (Hycamtin)FDA LinkGeneric 08/2009 - 08/2006
1	Fibroblast Growth Factor 1 (FGF-1)IBA 12/2023
1	LigandsIBA 12/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2023
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 12/2023
1	Protein Isoforms (Isoforms)IBA 11/2022
1	Immune Checkpoint InhibitorsIBA 02/2022
1	ChromatinIBA 01/2021
1	liposomal doxorubicin (Doxil)FDA Link 01/2020
1	thiaclopridIBA 01/2019
1	AutoantigensIBA 01/2018
1	anti-Yo autoantibodiesIBA 01/2018
1	temsirolimus FDA Link 03/2016
1	Tumor Biomarkers (Tumor Markers)IBA 09/2015
1	CA-125 Antigen (CA 125 Antigen)IBA 02/2011
1	treosulfanIBA 08/2009
1	Alkylating AgentsIBA 08/2009
1	Biological FactorsIBA 03/2009
1	human ERBB2 proteinIBA 01/2009
1	catumaxomabIBA 07/2007
1	Epithelial Cell Adhesion MoleculeIBA 07/2007
1	Gefitinib (Iressa)FDA Link 04/2007
1	Tamoxifen FDA LinkGeneric 04/2007
1	Matrix Metalloproteinase 7 (Matrilysin)IBA 01/2007
1	OligonucleotidesIBA 01/2007
1	Secretory Leukocyte Peptidase InhibitorIBA 01/2007
1	Kallikreins (Kallikrein)IBA 01/2007
1	OsteopontinIBA 01/2007
1	vasectrin IIIIBA 12/2006
1	Indicators and Reagents (Reagents)IBA 10/2006
1	Epirubicin (Ellence)FDA LinkGeneric 03/2006
1	HLA-DR Antigens (HLA-DR)IBA 06/2004
1	Fluorescein-5-isothiocyanate (FITC)IBA 06/2004

Therapy/Procedure

29	Drug Therapy (Chemotherapy) 01/2023 - 06/2002
22	Therapeutics 01/2023 - 01/2004
3	Cytoreduction Surgical Procedures 01/2023 - 12/2006
3	Lymph Node Excision (Lymph Node Dissection) 12/2020 - 04/2010
3	Immunotherapy 07/2007 - 03/2004
2	Combination Drug Therapy (Combination Chemotherapy) 01/2010 - 04/2006
1	Duration of Therapy 01/2023
1	Art Therapy 01/2020
1	Precision Medicine 01/2018
1	Operative Surgical Procedures 03/2013
1	Neoadjuvant Therapy 02/2012
1	Drug Tapering 04/2007
1	Time-to-Treatment 03/2006
1	TP protocol 02/2006